Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
101
datasets available to search
ShareScore release 0.9.0
Dataset results
101 results for “frontotemporal dementia”
Atrophy Pattern Maps of Frontotemporal Dementia variants (bvFTD, svPPA, pnfaPPA)
<p>The files contain voxel-wise t-statistics maps contrasting deformation based morphometry (DBM) measurements of frontotemporal dementia (FTD) patients, divided according to subtype diagnosis, against matched normal controls.</p> <p>BV = behavioral-variant Frontotemporal Dementia</p> <p>SV = semantic-variant Primary Progressive Aphasia</p> <p>PNFA = non-fluent-variant Primary Progressive Aphasia</p> <p> </p> <p>FTD map is based on NIFD data, available at: https://memory.ucsf.edu/research/studies/nifd</p> <p>For more information regarding the participants and method details, see:</p> <p>Dadar, Mahsa, et al. "White matter hyperintensities are associated with grey matter atrophy and cognitive decline in Alzheimer's disease and frontotemporal dementia." <em>Neurobiology of aging</em> 111 (2022): 54-63.</p> <p>Metz, Amelie, et al. "Brain Atrophy and White Matter Hyperintensities in Frontotemporal Dementia Variants and their Impact on Cognition" [Conference presentation] CCNA 2024 Partners Forum and Science Days (2024, March 19-21).</p>
Atrophy Pattern Maps of Alzheimer's Disease, Mild Cognitive Impairment, Parkinson's Disease, and Frontotemporal Dementia
<p>The files contain voxel-wise t-statistics maps contrasting deformation based morphometry (DBM) measurements of Alzheimer's disease (AD), Parkinson's disease (PD), mild cognitive impairment (MCI), and fronto-temporal dementia (FTD) patients against matched normal controls.</p> <p>AD and MCI maps are based on ADNI data, available at:</p> <p>PD map is based on PPMI data, available at:</p> <p>FTD map is based on NIFD data, available at:</p> <p>For more information regarding the participants and method details, see:</p> <p>Dadar, Mahsa, et al. "White matter hyperintensities are associated with grey matter atrophy and cognitive decline in Alzheimer's disease and frontotemporal dementia." <em>Neurobiology of aging</em> 111 (2022): 54-63.</p>
Deficiency of GRN, a frontotemporal dementia gene, results in gangliosidosis
<p>Haploinsufficiency of <em>GRN</em> causes frontotemporal dementia (FTD). The <em>GRN</em> locus produces progranulin (PGRN), which is cleaved to lysosomal granulin polypeptides. The function of lysosomal granulins and why their absence causes neurodegeneration are unclear. Here we discover that PGRN-deficient human cells and murine brains, as well as human frontal lobes from <em>GRN</em>-mutation FTD patients have increased levels of gangliosides, glycosphingolipids that contain sialic acid. In these cells and tissues, levels of lysosomal enzymes that catabolize gangliosides were normal, but levels of bis(monoacylglycero)phosphates (BMP), lipids required for ganglioside catabolism, were reduced with PGRN deficiency. Our findings indicate that granulins are required to maintain BMP levels to support ganglioside catabolism, and that PGRN deficiency in lysosomes leads to gangliosidosis. Lysosomal ganglioside accumulation may contribute to neuroinflammation and neurodegeneration susceptibility observed in FTD due to PGRN deficiency and other neurodegenerative diseases.</p>
datset related to article "NEUROSYPHILIS MIMICKING BEHAVIORAL VARIANT OF FRONTOTEMPORAL DEMENTIA IN A 59-YEAR-OLD MAN"
<p>neuropsychological data (raw data) of patient involved in the study at title</p>
Non-invasive Stimulation of Brain Networks and Cognition in Alzheimer's Disease and Frontotemporal Dementia
ClinicalTrials.gov study NCT03422250. IPD Sharing: NO. Countries: 1. Publications: 2.
Effects of Tolcapone on Frontotemporal Dementia
ClinicalTrials.gov study NCT00604591. IPD Sharing: NO. Countries: 1. Publications: 3.
Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia
ClinicalTrials.gov study NCT00545974. IPD Sharing: Not stated. Countries: 1. Publications: 26.
Supplementary material for: Neural effects of oxytocin and mimicry in frontotemporal dementia: A randomized cross-over study
<p><span>OBJECTIVE: Reduced empathy is one of the hallmark and untreatable symptoms of frontotemporal dementia (FTD). The objective of this study was to determine whether intranasal oxytocin, alone or in combination with instructed mimicry of facial expressions, would augment neural activity in patients with FTD in brain regions associated with empathy, emotion processing and the simulation network, as indexed by blood-oxygen-level dependent (BOLD) signal during functional magnetic resonance imaging (fMRI).</span></p> <p><span>METHODS: In a placebo-controlled, randomized cross-over design, 28 patients with FTD received 72 IU of intranasal oxytocin or placebo and then completed a fMRI facial expression mimicry task. </span></p> <p><span>RESULTS: Oxytocin alone, and in combination with instructed mimicry, increased activity in regions of the simulation network and in limbic regions associated with emotional expression processing. </span></p> <p><span>CONCLUSIONS: The findings demonstrate latent capacity to augment neural activity in affected limbic and other frontal and temporal regions during social cognition in patients with FTD, and support the promise and need for further investigation of these interventions as therapeutics in FTD.</span></p> <p><span><a>CLASSIFICATION OF EVIDENCE:</a> This study provides Class III evidence that a single dose of 72 IU intranasal oxytocin augments BOLD signal in patients with FTD during viewing of emotional facial expressions.</span></p>
Dataset related to article "Defective cyclophilin A induces TDP-43 proteinopathy: implications for amyotrophic lateral sclerosis and frontotemporal dementia"
<p>Dataset related to the article 10.1093/brain/awab333</p>
Data from: Cortical microstructure in the amyotrophic lateral sclerosis-frontotemporal dementia continuum
<p>Objective: We aimed to characterize cortical macro- and micro-structure of behavioral and cognitive changes along the amyotrophic lateral sclerosis (ALS) – frontotemporal dementia (FTD) continuum.</p> <p>Methods: We prospectively recruited 88 participants with a three-Tesla MRI structural and diffusion-weighted imaging sequences: 31 ALS, 20 bvFTD, and 37 cognitively normal controls. ALS participants underwent a comprehensive cognitive and behavioral assessment and were dichotomized in ALS without cognitive or behavioral impairment (ALSno-cbi, n=12) and ALS with cognitive or behavioral impairment (ALScbi, n=19). We computed cortical thickness and cortical mean diffusivity using a surface-based approach and explored the cortical correlates of cognitive impairment with the Edinburgh Cognitive and Behavioral Amyotrophic lateral sclerosis Screen (ECAS). </p> <p>Results: ALSno-cbi and ALScbi groups showed different patterns of reduced cortical thickness and increased cortical mean diffusivity. In the ALSno-cbi group, cortical thinning was mainly restricted to the dorsal motor cortex. In contrast, in the ALScbi group, cortical thinning was observed primarily on fronto-insular and temporal regions bilaterally. There were progressive cortical mean diffusivity changes along the ALSno-cbi, ALScbi, and bvFTD clinical continuum. Importantly, ALS participants with either cognitive or behavioral impairment showed increased cortical mean diffusivity in the prefrontal cortex in the absence of cortical thickness. </p> <p>Conclusions: Cortical mean diffusivity might be a useful biomarker for the study of extra motor cortical neurodegeneration in the ALS-FTD clinical spectrum.</p>
Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia
ClinicalTrials.gov study NCT00594737. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia
ClinicalTrials.gov study NCT01937013. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia
ClinicalTrials.gov study NCT00376051. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Safety Study of Intranasal Oxytocin in Frontotemporal Dementia
ClinicalTrials.gov study NCT01386333. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)
ClinicalTrials.gov study NCT04408625. IPD Sharing: Not stated. Countries: 6. Publications: 2.
Living With Frontotemporal Dementia
ClinicalTrials.gov study NCT01738386. IPD Sharing: Not stated. Countries: 1. Publications: 3.
A Study of the Behavioral Variant of Frontotemporal Dementia and Bipolar Disorder: a Neuroimaging and Epigenetics Integrated Approach
ClinicalTrials.gov study NCT06706687. IPD Sharing: NO. Countries: 1. Publications: 12.
Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD)
ClinicalTrials.gov study NCT00127114. IPD Sharing: Not stated. Countries: 1. Publications: 8.
Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
ClinicalTrials.gov study NCT00159198. IPD Sharing: Not stated. Countries: 1. Publications: 5.
Intranasal Oxytocin for Frontotemporal Dementia
ClinicalTrials.gov study NCT03260920. IPD Sharing: NO. Countries: 2. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.